Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review

DOI Web Site 参考文献333件 オープンアクセス
  • Shigekatsu Maekawa
    Department of Urology, Iwate Medical University, Iwate 028-3694, Japan
  • Ryo Takata
    Department of Urology, Iwate Medical University, Iwate 028-3694, Japan
  • Wataru Obara
    Department of Urology, Iwate Medical University, Iwate 028-3694, Japan

説明

<jats:p>The progression of prostate cancer (PCa) relies on the activation of the androgen receptor (AR) by androgens. Despite efforts to block this pathway through androgen deprivation therapy, resistance can occur through several mechanisms, including the abnormal activation of AR, resulting in castration-resistant PCa following the introduction of treatment. Mutations, amplifications, and splicing variants in AR-related genes have garnered attention in this regard. Furthermore, recent large-scale next-generation sequencing analysis has revealed the critical roles of AR and AR-related genes, as well as the DNA repair, PI3K, and cell cycle pathways, in the onset and progression of PCa. Moreover, research on epigenomics and microRNA has increasingly become popular; however, it has not translated into the development of effective therapeutic strategies. Additionally, treatments targeting homologous recombination repair mutations and the PI3K/Akt pathway have been developed and are increasingly accessible, and multiple clinical trials have investigated the efficacy of immune checkpoint inhibitors. In this comprehensive review, we outline the status of PCa research in genomics and briefly explore potential future developments in the field of epigenetic modifications and microRNAs.</jats:p>

収録刊行物

  • Cancers

    Cancers 16 (3), 523-, 2024-01-25

    MDPI AG

参考文献 (333)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ